No quantitative synthesis was attempted for either mebiomian plugging or meibomian secretion scores and no significant changes were observed with any other outcome parameter .
Conclusion : Only the systemic antimicrobials were found to improve the clinical features of meibomian gl and dysfunction .
Varying effects of different therapeutic agents ( heat therapies , omega-3-fatty acids and castor oil ) were identified for MGD but the risk of bias pertaining to r and omization and allocation concealment was found to be associated with most of the current RCTs .
Introduction : Meibomian Gl and Dysfunction ( MGD ) is a common , often overlooked , chronic condition affecting eyes for which various therapies are being evaluated .
Considering the absence of a systematic review and meta- analysis , the present review was carried out .
A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction
Purpose To evaluate the safety and effectiveness of the LipiFlow System compared to the iHeat Warm Compress ( WC ) for adults with meibomian gl and dysfunction ( MGD ) . Methods This was a non-significant risk , prospect i ve , open-label , r and omized , crossover multicenter clinical trial . One hundred thirty-nine subjects were r and omized between LipiFlow ( n=69 ) and WC control ( n=70 ) . Subjects in the LipiFlow group received a 12-minute LipiFlow treatment and were reexamined at 1 day , 2 weeks and 4 weeks . Control subjects received a 5-minute iHeat treatment with instructions to perform the same treatment daily for 2 weeks . At 2 weeks , they crossed over ( LipiFlow Crossover ) and received the LipiFlow  treatment . Effectiveness parameters : meibomian gl and ( MG ) assessment , tear break-up time ( TBUT ) and dry eye symptoms . Safety parameters : adverse events , ocular health exam , ocular surface staining , intraocular pressure , visual acuity and discomfort . Results LipiFlow result ed in significant improvement ( P < 0.05 ) in MG secretion at 2 and 4 weeks ( mean ± st and ard deviation at baseline = 6.3 ± 3.5 ; 2 weeks = 14.3 ± 8.7 ; 4 weeks = 16.7 ± 8.7 ) ; and TBUT at 2 and 4 weeks : ( at baseline = 5.5 ± 2.9 ; 2 weeks = 6.9 ± 5.0 ; 4 weeks = 7.4 ± 5.5 ) . There was no significant change in MG secretion or TBUT in the control group . LipiFlow result ed in a greater significant reduction in dry eye symptoms than the iHeat WC . The crossover group demonstrated similar significant improvement 2 weeks post-treatment with the LipiFlow . There was no significant difference between groups in the incidence of non-serious , device-related adverse events . Conclusion The LipiFlow System was significantly more effective than iHeat WC . These results support its safety and effectiveness in the treatment of MGD and dry eye symptoms
No quantitative synthesis was attempted for either mebiomian plugging or meibomian secretion scores and no significant changes were observed with any other outcome parameter .
Conclusion : Only the systemic antimicrobials were found to improve the clinical features of meibomian gl and dysfunction .
Varying effects of different therapeutic agents ( heat therapies , omega-3-fatty acids and castor oil ) were identified for MGD but the risk of bias pertaining to r and omization and allocation concealment was found to be associated with most of the current RCTs .
Introduction : Meibomian Gl and Dysfunction ( MGD ) is a common , often overlooked , chronic condition affecting eyes for which various therapies are being evaluated .
Considering the absence of a systematic review and meta- analysis , the present review was carried out .